Sanofi Genzyme Announces: FDA Accepts Its Resubmitted Application for Lemtrada/About-the-Society/News/Genzyme-Announces-FDA-Accepts-Its-Resubmitted-Appl … read morePosted At: National MS Society
Montana Activists Protect Access to Disease-Modifying Therapies in Montana/About-the-Society/News/Montana-Activists-Protects-Access-to-Disease-Modif … read morePosted At: National MS Society
Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS
Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSSMultiple Sclerosis Journal, Ahead of Print. … read morePosted At: MS Journal
Clinical outcome measures for progressive MS trialsMultiple Sclerosis Journal, Volume 23, Issue 12, Page 1627-1635, October 2017. … read morePosted At: MS Journal
Is the goal of an epigenomic study to determine causality?Multiple Sclerosis Journal, Volume 24, Issue 7, Page 908-909, June 2018. … read morePosted At: MS Journal
Join Our Mailing List
- What are the early signs of MS?
- Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis
- Treatment decisions in MS: Shifting the goal posts or changing how we see them?
- How to give an intramuscular injection
- Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry
- e-Health and multiple sclerosis: An update
- Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System
- Glutamate-sensitive imaging and evaluation of cognitive impairment in multiple sclerosis
- MS: Is a ‘rogue’ brain and lymph node interaction to blame?
- Zika virus found in brain tissue of a multiple sclerosis patient undergoing an acute disseminated encephalomyelitis-like episode